2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Assays, Molecular Testing, Emerging Technologies, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Non-Biological Therapies, Chemotherapy, Adverse Events, Biological Processes, Genomics, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Quality Improvement, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, Translational Research, CML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Study Population, Human, Adult
PAPER

1984 Phase II trial of dasatinib in combination with ASTX727 in patients with newly diagnosed chronic myeloid leukemia

Georgio Medawar, MD, Elias Jabbour, MD2, Fadi G. Haddad, MD3, Yesid Alvarado Valero, MD4, Musa Yilmaz, MD5, Nicholas Short, MD6, Hussein Ali Abbas, MD, PhD7, Joseph Castellano, MD8, Maria Villatoro9, Guillermo Montalban-Bravo, MD10, Sara Dellasala, BSc11, Guillermo Garcia-Manero, MD12, Ghayas C. Issa, MD13, Hagop Kantarjian, MD14
1 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
2 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
3 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
4 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
5 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
6 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
7 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
8 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
9 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
10 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
11 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
12 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
13 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
14 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Background

Decitabine has demonstrated activity in patients (pts) with advanced chronic myeloid leukemia (CML), and preclinical/early clinical data indicate that pairing decitabine with dasatinib might be synergistic. Building on this rationale, we hypothesized that adding ASTX727 (oral decitabine/cedazuridine) to dasatinib in newly diagnosed CML could deepen and prolong molecular responses, thereby increasing the proportion of pts eligible to pursue treatment-free remission (TFR). This study assesses the deep molecular response (DMR) rate achieved by combining dasatinib with ASTX727 in newly diagnosed chronic-phase CML (CML-CP), and to characterize the durability of response and long-term outcomes with extended follow-up.

 

Methods

In this phase II study, pts with newly diagnosed CML-CP started dasatinib 50 mg daily for 3 cycles; ASTX727 (fixed-dose combination of 100 mg cedazuridine/35 mg decitabine) was added beginning with Cycle 4, given on Days 1-3 of each 28-day cycle for up to 3 years. After the first 22 pts were enrolled, 2 (10%) developed Grade 4 neutropenia and thrombocytopenia requiring treatment interruption, leading to a protocol amendment to shorten ASTX727 dosing to Days 1-2 once DMR (BCR::ABL1 transcript <0.01% on the International Scale) was achieved. The primary endpoint was the MR4 rate after 6 months of combination therapy.

 

Results

Thirty-eight pts were enrolled; median age was 45 years (range, 21-68) and 28 (74%) were male, with 37 (97%) classified as low-intermediate Sokal risk. At a median follow-up of 39 months, the cumulative best response rates were CCyR in 97%, MMR in 84%, MR4 in 63%, and MR4.5 in 50% of pts. The primary endpoint, MR4 by 6 months of combination therapy (9 months from treatment start), was met in 32% of pts.

By 3 months of combination therapy (6 months overall), 84% of pts had achieved CCyR, 45% MMR, 18% MR4, and 5% MR4.5. By 9 months of combination therapy (12 months overall), among 36 evaluable pts, response rates rose to 92% CCyR, 61% MMR, 39% MR4, and 25% MR4.5. MR4 was ultimately reached in 55% of pts by 24 months, and 34% (13 pts) achieved and maintained sustained MR4 for a median duration of 25.6 months (range, 13.8-45.4).

Treatment-related adverse events were predominantly hematologic and included neutropenia (Grade 2, n=2; Grade 3-4, n=16) and thrombocytopenia (Grade 2, n=1; Grade 3-4, n=4), along with pleural effusion (Grade 1-2, n=2), fatigue (n=3), arthralgia (n=5), skin rash (n=2), ALT elevation (n=1), anemia (n=1), and heart failure (Grade 3, n=1).

Nine pts (24%) discontinued therapy overall for the following reasons: Toxicity (n=4; recurrent pleural effusion, cytopenias, fatigue/arthralgia, and heart failure - one pt each), blast-phase progression (n=1), pregnancy (n=1), financial hardship (n=1), and loss of response (n=2). One pt lost major cytogenetic response (MCyR) at 15 months, possibly reflecting a drug-drug interaction with semaglutide, with rising BCR::ABL1 transcripts despite dasatinib dose escalation to 100 mg/day; a second pt lost MCyR at 27 months while remaining on dasatinib 50 mg/day. No ABL1 kinase domain mutations were identified in either case. The 3-year rates of event-free survival (EFS), transformation-free survival (TFS) and overall survival (OS) were 89%, 97% and 97%, respectively.

While cross-trial comparisons have inherent limitations, molecular response rates achieved with dasatinib plus ASTX727 appeared broadly comparable to those historically reported with dasatinib monotherapy.

Conclusion

Dasatinib combined with ASTX727 represents a safe and effective frontline strategy for CML-CP, achieving high rates of CCyR and MMR with a manageable, primarily hematologic toxicity profile that was mitigated by shortening the duration of ASXT727 therapy. Continued follow-up is warranted to determine whether sustained DMR ultimately translates into higher rates of durable TFR in this population.

Georgio Medawar, MD: No relevant conflicts of interest to declare.